Compare PAR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | EWTX |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | PAR | EWTX |
|---|---|---|
| Price | $37.06 | $23.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $64.00 | $35.89 |
| AVG Volume (30 Days) | 607.0K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $440,451,000.00 | N/A |
| Revenue This Year | $30.40 | N/A |
| Revenue Next Year | $12.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.88 | N/A |
| 52 Week Low | $31.65 | $10.60 |
| 52 Week High | $81.51 | $35.50 |
| Indicator | PAR | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 60.50 |
| Support Level | $33.29 | $23.13 |
| Resistance Level | $38.15 | $24.66 |
| Average True Range (ATR) | 1.40 | 1.32 |
| MACD | 0.49 | -0.31 |
| Stochastic Oscillator | 81.49 | 31.79 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.